

Product datasheet for TP310319L

PHD3 (EGLN3) (NM_022073) Human Recombinant Protein

Product data:

Product Type: Recombinant Proteins Recombinant protein of human egl nine homolog 3 (C. elegans) (EGLN3), 1 mg **Description:** Species: Human HEK293T **Expression Host:** Expression cDNA Clone >RC210319 protein sequence or AA Sequence: Red=Cloning site Green=Tags(s) MPLGHIMRLDLEKIALEYIVPCLHEVGFCYLDNFLGEVVGDCVLERVKQLHCTGALRDGQLAGPRAGVSK RHLRGDQITWIGGNEEGCEAISFLLSLIDRLVLYCGSRLGKYYVKERSKAMVACYPGNGTGYVRHVDNPN GDGRCITCIYYLNKNWDAKLHGGILRIFPEGKSFIADVEPIFDRLLFFWSDRRNPHEVQPSYATRYAMTV WYFDAEERAEAKKKFRNLTRKTESALTED **TRTRPLEQKLISEEDLAANDILDYKDDDDKV** Tag: C-Myc/DDK Predicted MW: 27.1 kDa **Concentration:** >0.05 µg/µL as determined by microplate BCA method > 80% as determined by SDS-PAGE and Coomassie blue staining Purity: **Buffer:** 25 mM Tris-HCl, 100 mM glycine, pH 7.3, 10% glycerol Recombinant protein was captured through anti-DDK affinity column followed by **Preparation:** conventional chromatography steps. Note: For testing in cell culture applications, please filter before use. Note that you may experience some loss of protein during the filtration process. Store at -80°C. Storage: Stable for 12 months from the date of receipt of the product under proper storage and Stability: handling conditions. Avoid repeated freeze-thaw cycles. NP 071356 **RefSeq:** 112399 Locus ID: **UniProt ID:** Q9H6Z9



View online »

This product is to be used for laboratory only. Not for diagnostic or therapeutic use. ©2023 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

	PHD3 (EGLN3) (NM_022073) Human Recombinant Protein – TP310319L
RefSeq Size:	2722
Cytogenetics:	14q13.1
RefSeq ORF:	717
Synonyms:	HIFP4H3; HIFPH3; PHD3
Summary:	Cellular oxygen sensor that catalyzes, under normoxic conditions, the post-translational formation of 4-hydroxyproline in hypoxia-inducible factor (HIF) alpha proteins. Hydroxylates a specific proline found in each of the oxygen-dependent degradation (ODD) domains (N-terminal, NODD, and C-terminal, CODD) of HIF1A. Also hydroxylates HIF2A. Has a preference for the CODD site for both HIF1A and HIF2A. Hydroxylation on the NODD site by EGLN3 appears to require prior hydroxylation on the CODD site. Hydroxylated HIFs are then targeted for proteasomal degradation via the von Hippel-Lindau ubiquitination complex. Under hypoxic conditions, the hydroxylation reaction is attenuated allowing HIFs to escape degradation resulting in their translocation to the nucleus, heterodimerization with HIF1B, and increased expression of hypoxy-inducible genes. EGLN3 is the most important isozyme in limiting physiological activation of HIFs (particularly HIF2A) in hypoxia. Also hydroxylates PKM in hypoxia, limiting glycolysis. Under normoxia, hydroxylates and regulates the stability of ADRB2. Regulator of cardiomyocyte and neuronal apoptosis. In cardiomyocytes, inhibits the anti-apoptotic effect of BCL2 by disrupting the BAX-BCL2 complex. In neurons, has a NGF-induced proapoptotic effect, probably through regulating CASP3 activity. Also essential for hypoxic regulation of neutrophilic inflammation. Plays a crucial role in DNA damage response (DDR) by hydroxylating TELO2, promoting its interaction with ATR which is required for activation of the ATR/CHK1/p53 pathway. Target proteins are preferentially recognized via a LXXLAP motif.[UniProtKB/Swiss-Prot Function]
Protein Families:	Druggable Genome
Protein Pathways	Pathways in cancer, Renal cell carcinoma
Product image	25:

Product images:

 188

 98

 62

 49

 38

 28

 17

 33

Coomassie blue staining of purified EGLN3 protein (Cat# [TP310319]). The protein was produced from HEK293T cells transfected with EGLN3 cDNA clone (Cat# [RC210319]) using MegaTran 2.0 (Cat# [TT210002]).

This product is to be used for laboratory only. Not for diagnostic or therapeutic use. ©2023 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US